GAIN THERAPEUTICS INC

Gain Therapeutics Presents New Preclinical Data Demonstrating a Reduction of Plasma Neurodegeneration Biomarker NfL after Administration of its Drug Candidate GT-02287 in GBA1 Parkinson’s Disease Model

28 Aug 2023 07:00:00 By Nasdaq GlobeNewswire

Gain Therapeutics Announces Second Quarter 2023 Financial Results and Business Update

10 Aug 2023 07:00:01 By Nasdaq GlobeNewswire

Gain Therapeutics Announces Acceptance of Late Breaking Abstract for Presentation at the International Congress of Parkinson’s Disease and Movement Disorders®

07 Aug 2023 07:00:00 By Nasdaq GlobeNewswire

Gain Therapeutics to Participate in the 2023 BTIG Virtual Biotechnology Conference

31 Jul 2023 08:00:00 By Nasdaq GlobeNewswire

Gain Therapeutics to Present at the Jefferies Healthcare Conference

01 Jun 2023 08:00:01 By Nasdaq GlobeNewswire

Gain Therapeutics Reports First Quarter 2023 Financial Results and Business Update

12 May 2023 08:00:00 By Nasdaq GlobeNewswire

Gain Therapeutics Awarded CHF 2.5 million Innosuisse Grant to Advance Lead Program in GBA1 Parkinson’s Disease

03 May 2023 09:15:00 By Nasdaq GlobeNewswire

Gain Therapeutics Appoints C. Evan Ballantyne as Chief Financial Officer

12 Apr 2023 16:30:00 By Nasdaq GlobeNewswire

Gain Therapeutics to Present Positive Preclinical Data on its GBA1 Program at the AD/PD 2023 Meeting

29 Mar 2023 08:52:52 By Nasdaq GlobeNewswire

Gain Therapeutics Reports Full Year 2022 Financial Results and Business Update

23 Mar 2023 16:05:00 By Nasdaq GlobeNewswire

Gain Therapeutics to Participate in Virtual Fireside Chat On Computational Biology in Drug Discovery with Key Opinion Leaders

22 Mar 2023 08:30:00 By Nasdaq GlobeNewswire

Gain Therapeutics Announces Grant Award by Eurostars with Innosuisse for Alpha-1 Antitrypsin Deficiency Research Program

21 Mar 2023 08:00:01 By Nasdaq GlobeNewswire

Gain Therapeutics to Participate in the Oppenheimer 33rd Annual Healthcare Conference

09 Mar 2023 08:00:03 By Nasdaq GlobeNewswire

Gain Therapeutics Presents New Preclinical Data from its Gaucher Disease Program at the 19th Annual WORLDSymposium

27 Feb 2023 08:00:01 By Nasdaq GlobeNewswire

Gain Therapeutics to Participate in Upcoming Scientific and Medical Conferences

02 Feb 2023 08:00:00 By Nasdaq GlobeNewswire

Gain Therapeutics to Present at Sidoti Small-Cap Virtual Investor Conference

12 Jan 2023 16:05:00 By Nasdaq GlobeNewswire

Gain Therapeutics, Inc. Reports Third Quarter 2022 Financial Results and Business Update

10 Nov 2022 16:02:00 By Nasdaq GlobeNewswire

Gain Therapeutics Presents New Preclinical Data Showing Promising Pharmacological Activity in Parkinson’s Disease Patient-Derived Dopaminergic Neurons

26 Sep 2022 08:00:02 By Nasdaq GlobeNewswire

Gain Therapeutics Announces Promotion of Matthias Alder to Chief Executive Officer

20 Sep 2022 07:30:00 By Nasdaq GlobeNewswire

Gain Therapeutics Presents New Preclinical Data Demonstrating Potential Disease Modifying Benefits of its Novel Brain Penetrant Small Molecule Candidate GT-02287 in Two Preclinical Models of Parkinson’s Disease

19 Sep 2022 08:00:00 By Nasdaq GlobeNewswire